Background
The role of percutaneous repair of functional mitral regurgitation (MR) is evolving. Left ventricle remodeling is known to be different between men and women; however, outcomes following percutaneous repair of functional MR have not considered the impact of sex.
Methods
Between 2012 and 2018, 175 patients underwent percutaneous repair of functional MR with the Mitra Clip NT/NTR (Abbott) at our institution. Patients were assessed in a dedicated clinic with a follow‐up that averaged 0.7 ± 1.2 years and extended to 5.7 years.
Results
Men had a larger body surface area than women (p < .001), and were more likely than women to have diabetes preoperatively (p = .02). There were no deaths or instances of single leaflet detachment. Immediate postprocedure MR was ≤2+ in 158 (90%) with a mean trans‐mitral valve repair gradient of 3.4 ± 1.0 and 3.5 ± 2.1 mmHg, respectively for women and men (p = .8). One‐ and 2‐year freedom from MR ≥3+ was 86.0 ± 3.5% and 77.6 ± 5.1%, respectively. After adjusting for differences between male and female patients, women were more likely to have recurrent MR ≥3+ (hazard ratio, 4.7; 95% confidence interval, 1.2–18.4; p = .03). Upon adjusted analysis, there was also no association between gender and survival (p = .2). One‐ and 2‐year survival was 69.8 ± 4.3% and 54.3 ± 5.5%, respectively.
Conclusion
Women are more likely to have recurrent severe MR after percutaneous repair of functional MR. The mechanism for this remains undetermined.
Background The role of percutaneous repair of functional mitral
regurgitation (MR) is evolving. Left ventricle remodeling is known to be
different between men and women; however, outcomes following
percutaneous repair of functional MR have not considered the impact of
sex. Methods Between 2012 and 2018, 175 patients underwent percutaneous
repair of functional MR with the Mitra Clip NT/NTR (Abbott, Irvine CA)
at our institution. Patients were assessed in a dedicated clinic with a
follow-up that averaged 0.7±1.2 years and extended to 5.7 years. Results
Men had a larger body surface area than women (p<0.001),
whereas women were more likely than men to have diabetes preoperatively
(p=0.02). There were no deaths or instances of single leaflet
detachment. Immediate post-procedure MR was <2+ in 158 (90%)
with a mean trans-mitral valve repair gradient of 3.4±1.0 and 3.5±2.1 mm
Hg, respectively for women and men (p=0.8). One- and 2-year freedom from
MR >3+ was 86.0±3.5% and 77.6±5.1%, respectively. After
adjusting for differences between male and female patients, women were
more likely to have recurrent MR >3+ (hazard ratio 4.7,
95% confidence interval 1.2-18.4, p=0.03). Upon adjusted analysis,
there was also no association between gender and survival (p=0.2). One-
and 2- year survival was 69.8±4.3% and 54.3±5.5%, respectively.
Conclusion Women are more likely to have recurrent severe MR after
percutaneous repair of functional MR. The mechanism for this remains
undetermined.
We describe the case of a 64-year-old woman presenting with severe prosthetic mitral valve endocarditis 1 year after coronary artery bypass grafting and double valve replacement. Echocardiogram revealed high-pressure gradients through the bioprosthetic MV with a bulky vegetation. As the patient had presented operative difficulties due to severe mitral annular calcification, was in renal failure, and in the absence of any perivalvular involvement, an open-heart surgical catheter-based valve implantation was successfully performed after removal of the infected leaflets, leaving the stent frame and sewing cuff behind. Albeit controversial, this case represents an alternative approach for select high-risk reoperative mitral cases with mitral annular calcification.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.